KEGG results revealed that the 160 targets participated in more than 144 KEGG pathways, including Pathways in cancer, Prostate cancer, Lipid and atherosclerosis, EGFR tyrosine kinase inhibitor resistance, Proteoglycans in cancer, Endocrine resistance, PI3K-Akt signaling pathway, Apoptosis, Chemical carcinogenesis—reactive oxygen species, and Toxoplasmosis (Figure S3C). The gene discussed is AKT1; the disease is prostate carcinoma.